MetaADEDB 2.0 @ LMMD
Triptorelin Pamoate
(VXKHXGOKWPXYNA-PGBVPBMZSA-N)
Structure
SMILES
OC[C@@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)NCC(=O)N)CCCN=C(N)N)CC(C)C)Cc1c[nH]c2c1cccc2)Cc1ccc(cc1)O)NC(=O)[C@H](Cc1c[nH]c2c1cccc2)NC(=O)[C@@H](NC(=O)[C@@H]1CCC(=O)N1)Cc1[nH]cnc1
Type(s)
Approved; Vet_approved
ATC code(s)
L02AE04
Molecular Formula:
C64H82N18O13
Molecular Weight:
1311.450
Log P:
3.2000
Hydrogen Bond Acceptor:
28
Hydrogen Bond Donor:
17
TPSA:
490.42
CAS Number(s):
57773-63-4
Synonym(s)
1.
Triptorelin Pamoate
2.
D-Trp-6-LH-RH
3.
LHRH, Trp(6)-
4.
Triptorelin
5.
6-D-Tryptophan-Luteinizing Hormone-Releasing Factor (Pig)
6.
AY-25650
7.
CL-118532
8.
Decapeptyl
9.
Decapeptyl Depot
10.
Decapeptyl LP
11.
Decapeptyl Trimestral
12.
GnRH, Trp(6)-
13.
LHRH, Tryptophyl(6)-
14.
Trelstar
15.
Triptorelin Embonate
16.
Wy-42462
17.
AY 25650
18.
AY25650
19.
CL 118532
20.
CL118532
21.
Embonate, Triptorelin
22.
Pamoate, Triptorelin
23.
Trimestral, Decapeptyl
24.
Wy 42462
25.
Wy42462
External Link(s)
MeSHD017329
PubChem Compound25074470
ChEBI63633
CHEMBLCHEMBL1201334
DrugBankDB06825
DrugCentral2968
IUPHAR/BPS Guide to PHARMACOLOGY1177
KEGGdr:D06247
Therapeutic Target DatabaseD03QRS
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Product prescribing issueFAERS: 30US FAERS
2Drug ineffectiveFAERS: 28
Canada Vigilance: 1		Canada Vigilance
US FAERS
3Wrong technique in product usage processFAERS: 24US FAERS
4Product use complaintFAERS: 21US FAERS
5Syringe issueFAERS: 20US FAERS
6Incorrect dose administeredFAERS: 17US FAERS
7Needle issueFAERS: 16US FAERS
8Injection site painFAERS: 14SIDER
US FAERS
9FatigueFAERS: 13SIDER
US FAERS
10Emotional disorderFAERS: 11US FAERS
11HeadacheFAERS: 11SIDER
US FAERS
12Wrong technique in device usage processFAERS: 11US FAERS
13Accidental exposure to productFAERS: 10US FAERS
14Drug dose omissionFAERS: 10US FAERS
15Product dose omissionFAERS: 10US FAERS
16Product physical issueFAERS: 10US FAERS
17AstheniaFAERS: 9SIDER
US FAERS
18Abdominal PainFAERS: 8SIDER
US FAERS
19AcneFAERS: 8SIDER
US FAERS
20Inappropriate schedule of drug administrationFAERS: 8US FAERS
21Mood swingsFAERS: 8SIDER
US FAERS
22Product quality issueFAERS: 8US FAERS
23ArthralgiaFAERS: 6SIDER
US FAERS
24PainFAERS: 6SIDER
US FAERS
25AnxietyFAERS: 5SIDER
US FAERS
26Occupational exposure to productFAERS: 5US FAERS
27VomitingFAERS: 5SIDER
US FAERS
28AlopeciaFAERS: 4SIDER
US FAERS
29Back PainFAERS: 4SIDER
US FAERS
30Bone painFAERS: 4SIDER
US FAERS
31DizzinessFAERS: 4SIDER
US FAERS
32Drug administration errorFAERS: 4US FAERS
33Incorrect route of drug administrationFAERS: 4US FAERS
34Injury associated with deviceFAERS: 4US FAERS
35MyalgiaFAERS: 4SIDER
US FAERS
36NauseaFAERS: 4SIDER
US FAERS
37Personality ChangeFAERS: 4US FAERS
38Product physical consistency issueFAERS: 4US FAERS
39Product use issueFAERS: 4US FAERS
40PubertyFAERS: 4US FAERS
41ThrombocytopeniaFAERS: 4US FAERS
42UrticariaFAERS: 4SIDER
US FAERS
43AgitationFAERS: 3US FAERS
44Cerebrovascular accidentFAERS: 3SIDER
US FAERS
45Device defectiveFAERS: 3US FAERS
46Device difficult to useFAERS: 3US FAERS
47Disease ProgressionFAERS: 3US FAERS
48Medication ErrorFAERS: 3US FAERS
49MetrorrhagiaFAERS: 3US FAERS
50NasopharyngitisFAERS: 3SIDER
US FAERS
51NephrolithiasisFAERS: 3US FAERS
52OsteoporosisFAERS: 3US FAERS
53Product administration errorFAERS: 3US FAERS
54Product reconstitution quality issueFAERS: 3US FAERS
55Spontaneous penile erectionFAERS: 3US FAERS
56SyncopeFAERS: 3US FAERS
57Vaginal DischargeFAERS: 3US FAERS
58AmnesiaFAERS: 2US FAERS
59AngerFAERS: 2US FAERS
60AngioedemaFAERS: 2SIDER
US FAERS
61ApathyFAERS: 2US FAERS
62Atrial FibrillationFAERS: 2US FAERS
63Blood glucose increasedFAERS: 2SIDER
US FAERS
64Cerebral InfarctionFAERS: 2US FAERS
65Circumstance or information capable of leading to medication errorFAERS: 2US FAERS
66Depressed moodFAERS: 2US FAERS
67Drug exposure during pregnancyFAERS: 2US FAERS
68EpistaxisFAERS: 2
Canada Vigilance: 1		Canada Vigilance
SIDER
US FAERS
69Erectile dysfunctionFAERS: 2SIDER
US FAERS
70Feeling abnormalFAERS: 2SIDER
US FAERS
71FlushingFAERS: 2US FAERS
72Gastrointestinal hypomotilityFAERS: 2US FAERS
73Hormone level abnormalFAERS: 2US FAERS
74HypersensitivityFAERS: 2SIDER
US FAERS
75Injection related reactionFAERS: 2US FAERS
76Injection site noduleFAERS: 2US FAERS
77Intentional product misuseFAERS: 2US FAERS
78Joint stiffnessFAERS: 2SIDER
US FAERS
79MalaiseFAERS: 2SIDER
US FAERS
80MetastasisFAERS: 2SIDER
US FAERS
81Myocardial InfarctionFAERS: 2SIDER
US FAERS
82Product container issueFAERS: 2US FAERS
83Product preparation errorFAERS: 2US FAERS
84Product preparation issueFAERS: 2US FAERS
85Product solubility abnormalFAERS: 2US FAERS
86Product storage errorFAERS: 2US FAERS
87Renal ColicFAERS: 2US FAERS
88TachyphreniaFAERS: 2US FAERS
89VertigoFAERS: 2SIDER
US FAERS
90Weight decreasedFAERS: 2SIDER
US FAERS
91AbasiaFAERS: 1US FAERS
92Accessory breastFAERS: 1US FAERS
93Accidental underdoseFAERS: 1US FAERS
94Acute kidney injuryFAERS: 1US FAERS
95Acute myocardial infarctionFAERS: 1US FAERS
96Anaphylactic shockFAERS: 1SIDER
US FAERS
97AphasiaFAERS: 1US FAERS
98Autoimmune thyroiditisFAERS: 1US FAERS
99BelligerenceFAERS: 1US FAERS
100BlindnessFAERS: 1US FAERS
101Blood albumin decreasedFAERS: 1US FAERS
102Blood bilirubin unconjugated increasedFAERS: 1US FAERS
103Blood cholesterol increasedFAERS: 1US FAERS
104Blood creatine phosphokinase increasedFAERS: 1US FAERS
105Blood phosphorus increasedFAERS: 1US FAERS
106Blood sodium decreasedFAERS: 1US FAERS
107Blood testosterone abnormalFAERS: 1US FAERS
108Blood testosterone increasedFAERS: 1SIDER
US FAERS
109Blood triglycerides increasedFAERS: 1US FAERS
110Bone formation decreasedFAERS: 1US FAERS
111Bone lesionFAERS: 1US FAERS
112Bone marrow depressionFAERS: 1US FAERS
113Burning sensationFAERS: 1US FAERS
114CalcinosisFAERS: 1US FAERS
115Cell DeathFAERS: 1US FAERS
116Cerebral disorderFAERS: 1US FAERS
117Chest PainFAERS: 1SIDER
US FAERS
118ChillsFAERS: 1SIDER
US FAERS
119CholestasisFAERS: 1US FAERS
120ConstipationFAERS: 1SIDER
US FAERS
121Creatinine renal clearance decreasedFAERS: 1US FAERS
122CryingFAERS: 1US FAERS
123CytopeniaFAERS: 1US FAERS
124DeafnessFAERS: 1US FAERS
125DementiaFAERS: 1US FAERS
126Device FailureFAERS: 1US FAERS
127Device breakageFAERS: 1US FAERS
128Device malfunctionFAERS: 1US FAERS
129Device occlusionFAERS: 1US FAERS
130Device operational issueFAERS: 1US FAERS
131Dilated poresFAERS: 1US FAERS
132DiscomfortFAERS: 1SIDER
US FAERS
133DiverticulitisFAERS: 1US FAERS
134Drug level decreasedFAERS: 1US FAERS
135Dry skinFAERS: 1US FAERS
136DuodenitisFAERS: 1US FAERS
137DyscheziaFAERS: 1US FAERS
138DyschromatopsiaFAERS: 1US FAERS
139DyspepsiaFAERS: 1SIDER
US FAERS
140DystoniaFAERS: 1US FAERS
141DysuriaFAERS: 1SIDER
US FAERS
142Ectopic PregnancyFAERS: 1US FAERS
143Electrolyte imbalanceFAERS: 1US FAERS
144Emotional distressFAERS: 1US FAERS
145EnuresisFAERS: 1US FAERS
146GastritisFAERS: 1US FAERS
147HepatitisFAERS: 1US FAERS
148Histiocytosis haematophagicFAERS: 1US FAERS
149HypertrichosisFAERS: 1US FAERS
150HyperventilationFAERS: 1US FAERS
151HypotensionFAERS: 1SIDER
US FAERS
152ImmobileFAERS: 1US FAERS
153ImpatienceFAERS: 1US FAERS
154Incorrect dose administered by deviceFAERS: 1US FAERS
155Incorrect drug administration durationFAERS: 1US FAERS
156InfluenzaFAERS: 1SIDER
US FAERS
157Initial insomniaFAERS: 1US FAERS
158Injection site discomfortFAERS: 1US FAERS
159Joint swellingFAERS: 1SIDER
US FAERS
160Limb discomfortFAERS: 1US FAERS
161Liquid product physical issueFAERS: 1US FAERS
162Medical device complicationFAERS: 1US FAERS
163Memory impairmentFAERS: 1SIDER
US FAERS
164MenorrhagiaFAERS: 1US FAERS
165Migraine with AuraFAERS: 1US FAERS
166Musculoskeletal PainFAERS: 1SIDER
US FAERS
167Musculoskeletal chest painFAERS: 1US FAERS
168NervousnessFAERS: 1US FAERS
169NeuralgiaFAERS: 1US FAERS
170NocturiaFAERS: 1US FAERS
171Nodal osteoarthritisFAERS: 1US FAERS
172Oral painFAERS: 1US FAERS
173OsteopeniaFAERS: 1US FAERS
174PancytopeniaFAERS: 1US FAERS
175ParanoiaFAERS: 1US FAERS
176Pelvic massFAERS: 1US FAERS
177Pharyngolaryngeal PainFAERS: 1US FAERS
178Pneumatosis intestinalisFAERS: 1US FAERS
179PneumoniaFAERS: 1US FAERS
180PolyarthritisFAERS: 1US FAERS
181Poor quality product administeredFAERS: 1US FAERS
182Porphyria non-acuteFAERS: 1US FAERS
183PresyncopeFAERS: 1US FAERS
184Product administered at inappropriate siteFAERS: 1US FAERS
185Product administration interruptedFAERS: 1US FAERS
186Product complaintFAERS: 1US FAERS
187Product depositFAERS: 1US FAERS
188Product formulation issueFAERS: 1US FAERS
189Product packaging issueFAERS: 1US FAERS
190Prostatic specific antigen decreasedFAERS: 1US FAERS
191PruritusFAERS: 1SIDER
US FAERS
192PyelonephritisFAERS: 1US FAERS
193Retinitis PigmentosaFAERS: 1US FAERS
194SciaticaFAERS: 1US FAERS
195Skin necrosisFAERS: 1US FAERS
196SomnolenceFAERS: 1SIDER
US FAERS
197Subcutaneous noduleFAERS: 1US FAERS
198Sudden deathFAERS: 1US FAERS
199Therapeutic product effect decreasedFAERS: 1US FAERS
200Thyroid hormones increasedFAERS: 1US FAERS
201ToxocariasisFAERS: 1US FAERS
202TremorFAERS: 1US FAERS
203Urinary tract infectionFAERS: 1SIDER
US FAERS
204VasculitisFAERS: 1US FAERS
205Visual ImpairmentFAERS: 1SIDER
US FAERS
206fibromaFAERS: 1US FAERS
207Acute Coronary SyndromeSIDER
208Alanine Aminotransferase IncreasedSIDER
209AnorexiaSIDER
210Aspartate Aminotransferase IncreasedSIDER
211Bladder neck obstructionSIDER
212Blood alkaline phosphatase increasedSIDER
213Blood and lymphatic system disordersSIDER
214Blood creatinine increasedSIDER
215Blood testosterone decreasedSIDER
216Blood urea increasedSIDER
217Breast pain maleSIDER
218BronchitisSIDER
219ConjunctivitisSIDER
220Cramps of lower extremitiesSIDER
221Deep Vein ThrombosisSIDER
222DermatitisSIDER
223Diabetes MellitusSIDER
224Disturbance in sexual arousalSIDER
225DysgeusiaSIDER
226Ear and labyrinth disordersSIDER
227EmbolismSIDER
228Euphoric moodSIDER
229Eye painSIDER
230FlatulenceSIDER
231Gastrointestinal PainSIDER
232Glucose increasedSIDER
233GoutSIDER
234Hormone-dependent prostate cancerSIDER
235HypokinesiaSIDER
236InfectionSIDER
237InfestationSIDER
238InflammationSIDER
239Injection Site ReactionSIDER
240Injection site erythemaSIDER
241Leg edemaSIDER
242LethargySIDER
243Local reactionSIDER
244Lymphocyte count increasedSIDER
245LymphocytosisSIDER
246MalnutritionSIDER
247Metastatic painSIDER
248Musculoskeletal discomfortSIDER
249Musculoskeletal stiffnessSIDER
250NeuropathySIDER
251OphthalmoplegiaSIDER
252PalpitationsSIDER
253Paresthesia lower limbSIDER
254PharyngitisSIDER
255Pituitary AdenomaSIDER
256Pituitary ApoplexySIDER
257Pituitary infarctionSIDER
258PurpuraSIDER
259RhinitisSIDER
260Serum testosterone increasedSIDER
261ShockSIDER
262ThrombophlebitisSIDER
263TinnitusSIDER
264Urethral ObstructionSIDER
265Urinary RetentionSIDER
266Vascular purpuraSIDER
267Visual disturbanceSIDER
268nervous system disorderSIDER
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120235

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.